A PHASE 2, OPEN-LABEL, MONOTHERAPY, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INCB054828 IN SUBJECTS WITH MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT

Registry ID

INCB 54828-203

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

INCYTE CORPORATION

Start date

2021-10-15

Completion date

2025-03-28

Last update

2018-11-29

Conditions

• LYMPHOID MALIGNANCIES
• MYELOID MALIGNANCIES

Related clinical trials

• A PHASE 1, DOSE-ESCALATION/DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF ORALLY ADMINISTERED CB-5083 IN SUBJECTS WITH LYMPHOID HEMATOLOGICAL MALIGNANCIES
• A PHASE I/II STUDY OF PEMBROLIZUMAB (MK-3475) IN CHILDREN WITH ADVANCED MELANOMA OR A PD-L1 POSITIVE ADVANCED, RELAPSED OR REFRACTORY SOLID TUMOR OR LYMPHOMA (KEYNOTE-051)

View on source registry